Mayor Greg Ballard to Join Roche Diagnostics Leaders at Groundbreaking of New Learning and Development Center

Mayor Greg Ballard to Join Roche Diagnostics Leaders at Groundbreaking of New
                       Learning and Development Center

Mayor, company and community leaders to break ground and unveil renderings of
key element of recently announced $300 million site transformation investment

PR Newswire

INDIANAPOLIS, Nov. 12, 2012

INDIANAPOLIS, Nov. 12, 2012 /PRNewswire/ --Roche Diagnostics, a world leader
in pharmaceuticals and diagnostics, announced in June its plans to invest $300
million during the next 10 years in expanding its North American headquarters
located on the northeast side of Indianapolis. The first phase of the project
is a new Learning and Development Center, where approximately 1,500 customers
from across the nation will be trained each year.

Mayor Greg Ballard will be joined by Roche Diagnostics President and CEO Jack
Phillips along with members of the City-County Council and community leaders
to break ground on the expansion and unveil renderings of the new building,
which will have a distinct architectural style.

WHO:   Mayor Greg Ballard
                  Jack Phillips, President and CEO, Roche Diagnostics
                  Members of City-County Council
WHEN:   Wednesday, November 14, 2012
                  10:00 A.M. Eastern Standard Time
WHAT:   Groundbreaking Ceremony for Roche Diagnostics Learning and
                  Development Center
WHERE:     Roche Diagnostics Campus – Near Entrance 4
                  9115 Hague Road, Indianapolis, Indiana
RSVP: Please RSVP to Jacque Robertson at
                  jacque.robertson@roche.com or (317) 521-2819
                  Due to limited parking on corporate campus, RSVPs are
                  appreciated.
NOTE:  Press riser with mult box to be provided. Principals will
                  be made available to press following event.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer
in diabetes management. Roche's personalized healthcare strategy aims at
providing medicines and diagnostic tools that enable tangible improvements in
the health, quality of life and survival of patients. In 2011, Roche had over
80,000 employees worldwide and invested over 8 billion Swiss francs in R&D.
The Group posted sales of 42.5 billion Swiss francs. Genentech, United States,
is a wholly owned member of the Roche Group. Roche has a majority stake in
Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Todd Siesky
Director, Corporate Communications

Roche Diagnostics

Indianapolis, IN
(317) 521-3966 O

(317) 361-7637 C
todd.siesky@roche.com





SOURCE Roche Diagnostics, Inc.

Website: http://www.roche.com
 
Press spacebar to pause and continue. Press esc to stop.